Madrigal Pharmaceuticals Inc

MDGL

NASDAQ. Currency in USD

234.83 +171.03 ( +268.07% )

Real time prices: December 19

Market Cap.
4.02B
Beta (5Y monthly)
0.89
Price/Earnings
-
EPS (TTM)
-16.03
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
8.71M
1y Target Est.
152.58
Day's Range
191.49
-
236.39
52 Week's Range
54.34
-
236.39

Historical Summary

Performance
EPS growth
Share Buybacks

About Madrigal Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.madrigalpharma.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
17.10M
Employees
71
Address
Four Tower Bridge, West Conshohocken, PA, United States, 19428
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Latest news

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

CONSHOHOCKEN, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage...
By GlobeNewswire Inc. - 20 weeks ago

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results

CONSHOHOCKEN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical...
By GlobeNewswire Inc. - 25 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

Upgrades According to Wedbush, the prior rating for Diebold Nixdorf Inc (NYSE:DBD) was changed from...
By Benzinga - 29 weeks ago

Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

CONSHOHOCKEN, Pa., June 25, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical...
By GlobeNewswire Inc. - 31 weeks ago

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

CONSHOHOCKEN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage...
By GlobeNewswire Inc. - 34 weeks ago

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage...
By GlobeNewswire Inc. - 36 weeks ago

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results

Company to host conference call at 8:00 AM ET, May 9th, 2022
By GlobeNewswire Inc. - 38 weeks ago

Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage...
By GlobeNewswire Inc. - 46 weeks ago